ImmunoGen Inc reports results for the quarter ended in December - Earnings Summary

ImmunoGen

01/03/2023 14:32

* ImmunoGen Inc  IMGN.OQ  reported a quarterly adjusted loss
of 23
cents​​ per share for the quarter ended in December. The mean
expectation of twelve analysts for the quarter was for a loss
of 30 cents per share.
    * Revenue rose 47.1% to $41.17 million from a year ago;
analysts
expected $17.25 million. 
    * ImmunoGen Inc's reported EPS for the quarter was a loss
of 23
cents​.
    * The mean earnings estimate of analysts had fallen by
about 2.3%
in the last three months.​ 
    * In the last 30 days there have been no negative revisions
of
earnings estimates 
    * ImmunoGen Inc shares had fallen by 21.8% this quarter.
    * The company reported a quarterly loss of $59.01 million.
    * Wall Street's median 12-month price target for ImmunoGen
Inc is
$12.00 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 9 "strong buy" or "buy," 3
"hold" and no "sell" or "strong sell." 

This summary was machine generated from Refinitiv data March 1
at 02:32 p.m.  ​All figures in US dollars unless otherwise
stated. QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,
                                                 MISSED
 Dec. 31 2022      -0.30          -0.23          Beat
 Sep. 30 2022      -0.25          -0.31          Missed
 Jun. 30 2022      -0.21          -0.24          Missed
 Mar. 31 2022      -0.21          -0.10          Beat